tiprankstipranks
Blurbs

Robert W. Baird Assigns a Hold Rating on Allogene Therapeutics (ALLO)

In a report issued on June 8, Jack Allen from Robert W. Baird assigned a Hold rating to Allogene Therapeutics (ALLOResearch Report), with a price target of $11.00. The company’s shares closed last Thursday at $10.75.

According to TipRanks.com, Allen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.5% and a 25.8% success rate. Allen covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, Intellia Therapeutics, and Decibel Therapeutics.

Currently, the analyst consensus on Allogene Therapeutics is a Moderate Buy with an average price target of $19.83, representing a 90.7% upside. In a report issued on May 24, Goldman Sachs also maintained a Hold rating on the stock with a $9.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $27.86 and a one-year low of $6.43. Currently, Allogene Therapeutics has an average volume of 1.85M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Read More on ALLO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More